Stay updated on NILE Clinical Trial: Durvalumab Combo in Unresectable Urothelial Cancer
Sign up to get notified when there's something new on the NILE Clinical Trial: Durvalumab Combo in Unresectable Urothelial Cancer page.

Latest updates to the NILE Clinical Trial: Durvalumab Combo in Unresectable Urothelial Cancer page
- Check5 days agoNo Change Detected
- Check12 days agoNo Change Detected
- Check19 days agoChange DetectedPage now shows a newer date and updated study-status entry, replacing an older date; overall meaning shifts toward current status information without affecting core transactional elements.SummaryDifference0.6% 
- Check26 days agoChange Detected- Added a government funding lapse notice and current operating status guidance for NIH Clinical Center, and a version bump to v3.2.0. - Removed the previous version tag v3.1.0.SummaryDifference9% 
- Check33 days agoChange DetectedVersion updated from v3.0.2 to v3.1.0; no substantive content changes detected.SummaryDifference0.2% 
- Check48 days agoChange Detected- Updated revision from v3.0.1 to v3.0.2 and removed the 'Back to Top' element.SummaryDifference0.5% 
- Check55 days agoChange DetectedThe web page has been updated from version 3.0.0 to version 3.0.1, indicating a revision in the content. There are no significant changes to core content or important information.SummaryDifference0.5% 
- Check62 days agoChange DetectedThe web page has undergone significant updates, including the addition of a facility name and location details, while removing specific location terms and listed countries. This indicates a shift towards a more streamlined presentation of study status information.SummaryDifference55% 
Stay in the know with updates to NILE Clinical Trial: Durvalumab Combo in Unresectable Urothelial Cancer
Enter your email address, and we'll notify you when there's something new on the NILE Clinical Trial: Durvalumab Combo in Unresectable Urothelial Cancer page.